Why the study?
Does I.C.I. 50172 improve exercise tolerance in normal subjects and patients with angina pectoris?
Does I.C.I. 50172 improve exercise tolerance in normal subjects and patients with angina pectoris?
I.C.I. 50172, a cardio-selective beta-blocker, significantly increases exercise tolerance in patients with angina pectoris and may be safe in patients with comorbid asthma.
May increase exercise tolerance in angina comparably to propranolol; leaves open confirmation of cardio-selectivity benefits in larger trials.
A cardio-selective beta-adrenergic blocking agent (I.C.I. 50172), which has been studied both in normal subjects and in patients with angina pectoris during and after a standardized work test, produced a significant increase in the exercise tolerance of the patients. These favourable effects are comparable with those of propranolol.One patient with severe bronchial asthma and coronary insufficiency treated with I.C.I. 50172 improved and his respiratory function was not impaired.
No takes yet. Share an insight, caveat, or question.
Areskog et al. (1969) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: